NVS vs SRRK
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
Side-by-side fundamentals
| Metric | NVS | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.08 | $48.30 | |
| Market cap as of 2026-07-23 | $229.2B | $5.9B | |
| P/E as of 2026-07-23 | 22.11 | n/a | |
| PEG as of 2026-07-23 | 3.66 | -0.40 | SRRK lower |
| Net margin as of 2026-07-23 | +22.5% | -237.0% | NVS higher |
| Gross margin as of 2026-07-23 | +75.0% | n/a | |
| Operating margin as of 2026-07-23 | +29.9% | -231.8% | NVS higher |
| ROE as of 2026-07-23 | +29.9% | -162.9% | NVS higher |
| ROA as of 2026-07-23 | +11.1% | -96.3% | NVS higher |
| Debt / equity as of 2026-07-23 | 1.18 | 0.71 | SRRK lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.3% | n/a | |
| Dividend yield as of 2026-07-23 | +3.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | 0.65 | |
| 1-year return as of 2026-07-22 close | +35.8% | +20.8% | NVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.